Targeting Wnt signaling for improved glioma immunotherapy.

ICG-001 NanoString gene expression Wnt signaling, pathway differentiation glioma immunotherapy proteomics

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 22 11 2023
accepted: 29 01 2024
medline: 7 3 2024
pubmed: 7 3 2024
entrez: 7 3 2024
Statut: epublish

Résumé

Despite aggressive standard-of-care therapy, including surgery, radiation, and chemotherapy, glioblastoma recurrence is almost inevitable and uniformly lethal. Activation of glioma-intrinsic Wnt/β-catenin signaling is associated with a poor prognosis and the proliferation of glioma stem-like cells, leading to malignant transformation and tumor progression. Impressive results in a subset of cancers have been obtained using immunotherapies including anti-CTLA4, anti-PD-1, and anti-PD-L1 or chimeric antigen receptor (CAR) T cell therapies. However, the heterogeneity of tumors, low mutational burden, single antigen targeting, and associated antigen escape contribute to non-responsiveness and potential tumor recurrence despite these therapeutic efforts. In the current study, we determined the effects of the small molecule, highly specific Wnt/CBP (CREB Binding Protein)/β-catenin antagonist ICG-001, on glioma tumor cells and the tumor microenvironment (TME)-including its effect on immune cell infiltration, blood vessel decompression, and metabolic changes. Using multiple glioma patient-derived xenografts cell lines and murine tumors (GL261, K-Luc), we demonstrated In these glioma cell lines, we further demonstrated that ICG-001 downregulated the CBP/β-catenin target gene We conclude that specific Wnt/CBP/β-catenin antagonism results in pleotropic changes in the glioma TME, including glioma stem cell differentiation, modulation of the stroma, and immune cell activation and recruitment, thereby suggesting a possible role for enhancing immunotherapy in glioma patients.

Identifiants

pubmed: 38449858
doi: 10.3389/fimmu.2024.1342625
pmc: PMC10915090
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1342625

Informations de copyright

Copyright © 2024 Gutova, Hibbard, Ma, Natri, Adhikarla, Chimge, Qiu, Nguyen, Melendez, Aguilar, Starr, Yin, Rockne, Ono, Banovich, Yuan, Brown and Kahn.

Déclaration de conflit d'intérêts

MK is a cofounder and holds equity in 3 + 2 Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Margarita Gutova (M)

Department of Stem Cell Biology and Regenerative Medicine, City of Hope Beckman Research Institute, Duarte, CA, United States.

Jonathan C Hibbard (JC)

Department of Hematology & Hematopoietic Cell transplantation (T cell Therapeutic Research Laboratories), City of Hope Beckman Research Institute, Duarte, CA, United States.

Eric Ma (E)

Department of Hematology & Hematopoietic Cell transplantation (T cell Therapeutic Research Laboratories), City of Hope Beckman Research Institute, Duarte, CA, United States.

Heini M Natri (HM)

Translational Genomics Research Institute (TGen), Phoenix, AZ, United States.

Vikram Adhikarla (V)

Division of Mathematical Oncology, Department of Computational and Quantitative Medicine, City of Hope Beckman Research Institute, Duarte, CA, United States.

Nyam-Osor Chimge (NO)

Cancer Biology and Molecular Medicine, City of Hope Beckman Research Institute, Duarte, CA, United States.

Runxiang Qiu (R)

Department of Stem Cell Biology and Regenerative Medicine, City of Hope Beckman Research Institute, Duarte, CA, United States.

Cu Nguyen (C)

Cancer Biology and Molecular Medicine, City of Hope Beckman Research Institute, Duarte, CA, United States.

Elizabeth Melendez (E)

Cancer Biology and Molecular Medicine, City of Hope Beckman Research Institute, Duarte, CA, United States.

Brenda Aguilar (B)

Department of Hematology & Hematopoietic Cell transplantation (T cell Therapeutic Research Laboratories), City of Hope Beckman Research Institute, Duarte, CA, United States.

Renate Starr (R)

Department of Hematology & Hematopoietic Cell transplantation (T cell Therapeutic Research Laboratories), City of Hope Beckman Research Institute, Duarte, CA, United States.

Holly Yin (H)

Cancer Biology and Molecular Medicine, City of Hope Beckman Research Institute, Duarte, CA, United States.

Russel C Rockne (RC)

Division of Mathematical Oncology, Department of Computational and Quantitative Medicine, City of Hope Beckman Research Institute, Duarte, CA, United States.

Masaya Ono (M)

National Cancer Center, Tokyo, Japan.

Nicholas E Banovich (NE)

Translational Genomics Research Institute (TGen), Phoenix, AZ, United States.

Yate-Ching Yuan (YC)

Department of Computational and Quantitative Medicine, City of Hope Beckman Research Institute, Duarte, CA, United States.

Christine E Brown (CE)

Department of Hematology & Hematopoietic Cell transplantation (T cell Therapeutic Research Laboratories), City of Hope Beckman Research Institute, Duarte, CA, United States.

Michael Kahn (M)

Cancer Biology and Molecular Medicine, City of Hope Beckman Research Institute, Duarte, CA, United States.

Classifications MeSH